![](https://www.signifyresearch.net/wp-content/uploads/2024/05/SPI-MI-CerebraAI-Image-WP-564x420.jpg)
Written by
![Phil Grainger headshot](https://www.signifyresearch.net/wp-content/uploads/2023/12/Phil-Grainger-150x150.jpg)
Phil Grainger
![Ellie Baker headshot](https://www.signifyresearch.net/wp-content/uploads/2023/12/Ellie-copy-150x150.png)
Ellie Baker
![Bhvita Jani headshot](https://www.signifyresearch.net/wp-content/uploads/2023/12/Signify-Bhvita_J-Profile-@2-150x150.png)
Bhvita Jani
CerebraAI, an AI-driven neuroradiology software company focused on acute ischemic stroke detection, has relocated its headquarters from Kazakhstan to the Silkroad Innovation Hub in Silicon Valley. The company aims to enhance non-contrast CT (NCCT) scans to diagnose ischemic stroke through a novel approach.
CerebraAI’s solution is based upon brain imaging analysis maps, using AI-generated images of the patient’s pseudo-healthy brain. The vendor claims that its technology is as sensitive as an MRI in detecting acute ischemic strokes.
This unique approach to stroke detection presents challenges and opportunities for CerebraAI as it enters the US market.
Read the full insight with a Signify Premium Insights - Healthcare IT subscription